Small molecules that induce protein degradation through ligase-mediated ubiquitination have shown considerable promise as a new pharmacological modality. We and others have demonstrated that efficacious degradation of kinases and other targets can be achieved in vitro and in vivo, however, many targets remain recalcitrant to degradation. In this presentation, I will discuss the use of high throughput chemical-proteomics approaches to map protein degradability and accelerate the development of degraders as novel chemical probes for therapeutic targets such as protein kinases.